A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Condition: CancerInterventions: Drug: Trametinib 0.5 mg; Drug: Trametinib 2 mg; Drug: ORTHO-NOVUM® tablet 1/35; Drug: PlaceboSponsor: GlaxoSmithKlineNot yet recruiting - verified November 2014

http://clinicaltrials.gov/ct2/show/NCT02292732?lup_s=10%2F19%2F2014&lup_d=30

Source: ClinicalTrials.gov - November 13, 2014 Category: Research Source Type: clinical trials